BTPS: Improving Asset Quality and Capital Return at Indonesian Lender

May 6, 2026 in Asia, Asian Investing Summit 2026, Asian Investing Summit 2026 Featured, Audio, Discover Great Ideas Podcast, Equities, Ideas, Member Podcasts, Transcripts

Florian Weidinger of Santa Lucia Asset Management presented his investment thesis on BTPN Syariah (Indonesia: BTPS) at Asian Investing Summit 2026.

Thesis summary:

BTPN Syariah is a fully licensed Indonesian bank that engages exclusively in Yunus/Grameen-style microfinance, extending $100-$200 loans to female-only borrower groups that provide mutual guarantee, with cycle-based graduation as borrowers establish payment discipline. The company is 70%-owned by Bank BTPN, the Indonesian listed subsidiary of SMBC. Florian views BTPS as an overcapitalized “fallen angel” that once traded at 6x P/B and recently traded at 0.7x P/B following a reset in fundamentals that, in his view, has now turned.

The business carries atypical bank ratios, including a 59% CET1 ratio and 44% equity-to-assets. BTPS lends at 25-30% rates against a low-single-digit cost of funds; opex runs at half of net interest income, while cost of credit has improved toward 5%. Florian highlights an improving “x-days” metric (1-30 days past due), rising attendance at borrower group meetings, and management guidance of high-single-digit net profit growth as ROE recovers toward the high teens.

Florian attributes the dislocation to a delayed reckoning from COVID, when collection agents could not visit villages and behavioral cycles broke down, compounded in 2021-22 by VC-backed fintech lenders flooding rural Indonesia with cheap credit that masked underlying delinquency. The bill came due in 2023-24, prompting investor capitulation. Sentiment toward Indonesian equities sits at multi-year lows. BTPS could benefit from President Prabowo’s pro-rural policy tilt as well as MSCI-driven cleanup of the central registry that should redirect retail flows toward fundamentals.

Engagement with management has yielded a share buyback program announced last year. After the share price recovered out of the buyback window, recent weakness has reopened the opportunity for resumption. Separately, BPJS TK has announced a planned increase in domestic equity exposure from 11% to 20-25%, which could improve the underlying bid for Indonesian equities broadly.

The shares recently traded at 0.7x P/B, ~5.6x forward P/E, and a trailing 7.6% dividend yield, with a forward yield likely above 8%. Florian argues that a lender capable of generating high-teens-to-20% ROE with continued growth should not trade below book; a target multiple of 1.1-1.5x P/B appears reasonable as evidence accumulates that the COVID experience is fully provisioned. A resumed buyback at a 30% discount to book would be accretive to per-share book value. Key risks include IDR weakness and potential government intervention through subsidized or state-led microfinance competition.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Florian Weidinger is the CEO of Santa Lucia Asset Management (SLAM), a pan-Asian Singapore-based investment management business. Prior, he was the founder of Hansabay a specialist in active engagement and special situation investing, and one of the early adopters of the PRI Principles for Responsible Investment in Singapore. Hansabay contributed its activities into SLAM during 2021. Earlier in his career, Florian Weidinger was a vice president at Lehman Brothers where he last worked for the insolvency administration, after several years with the risk arbitrage, principal investing and investment banking divisions in London. Mr. Weidinger has sourced, managed and executed public and private investments in Europe, Africa and Asia, and across the capital structure. Strategies included event-driven, long/short, distressed/credit and special situations investing. Mr. Weidinger has held multiple board directorships across sectors, including in the public markets. Mr. Weidinger holds a BSc from City University London, an MBA from the Stanford Graduate School of Business, and an MS in Environment and Resources from Stanford University’s School of Earth Sciences.

The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.

Indigo Paints: Founder-Led Compounder at a Reset Multiple

May 2, 2026 in Asia, Asian Investing Summit 2026, Asian Investing Summit 2026 Featured, Audio, Equities, Ideas

Mehul Bhatt of OysterRock Capital presented his in-depth investment thesis on Indigo Paints (India: INDIGOPNTS) at Asian Investing Summit 2026.

Thesis summary:

Indigo Paints is the #5 player in India’s $10 billion paints and coatings industry, which Mehul expects to grow at high-single-digit to low-double-digit rates to roughly $15 billion over the next four years. Founded in 2000 by Hemant Jalan (IIT Kanpur, Stanford, Chicago Booth) with a single cement-paint product, Indigo has grown into a five-plant, 28-state operation with 20,000 active dealers, 12,000 tinting machines, and 55 depots, serving an industry historically dominated by Asian Paints, Berger, Kansai Nerolac, and Akzo Nobel. Decorative paints account for ~75% of the market and benefit from shortening repainting cycles, urbanization, premiumization, and ongoing formalization, with organized share already at ~75% and rising.

Indigo built its base by targeting Tier 3/4/5 towns and rural India, fighting unorganized players rather than incumbents and initially generating ~75% of revenue from those markets. Product innovation in specialty decoratives—metallic emulsions, tile coats, ceiling coats—now contributes 25–30% of revenue at higher margins. From FY23 onward, the company has pushed into Tier 1/2 cities, which now contribute roughly two-thirds of revenue.

The thesis hinges on undiscounted change. The entry of Birla Opus disrupted industry pricing and trade discipline, compressing margins across the sector and producing a flat FY25 for Indigo (revenue of ₹13.4 billion, OPM of 17%). To defend profitability, management cut A&P spend from 8% to 5.5% of revenue. Mehul expects competitive intensity to rationalize as incumbents recalibrate, allowing Indigo’s distribution moat and product innovation to drive a return to industry-leading growth.

Near-term catalysts include the June 2026 commissioning of the Jodhpur water-based paint plant (90,000 KLPA) and the scaling of recently acquired Apple Chemie (51% stake), a construction chemicals and waterproofing business with B2B credentials on flagship infrastructure projects (MTHL, Atal Setu), currently at ₹50 crore (~$5 million) of revenue, targeted to reach ₹200 crore (~$20 million) within two to three years.

The shares recently traded at ₹780, a market cap of ₹38 billion, ~25x trailing earnings, ~16x EV/EBITDA, and 3.6x book—well below FY24’s P/E of 32 and a fraction of post-IPO multiples. The balance sheet carries negligible debt, ROCE of ~27%, and ROE of ~15%, with annual operating cash flow of roughly $25 million. Mehul’s view is that a return to low-teens revenue growth, combined with margin recovery toward the 17–19% range, sets up a favorable risk/reward as Indigo’s transition completes.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Mehul Bhatt is the Founder and Managing Partner at OysterRock Capital, a eight-year-old India-centric fund manager founded in Mumbai. The firm manages an onshore India fund and has Luxembourg and Mauritius vehicles where it accepts international investments for investing in Indian equities. OysterRock’s thesis of “Capturing Undiscounted Change” and capturing perception variance between businesses and markets are areas where the firm has seen extraordinary outcomes. The firm has compounded at > 18% over the last 8 years by identifying companies that are in transition and by combining deep analysis with “scuttle-butt”, it has seen success in companies like Gabriel India (9x), Laurus Labs (10x), and Polymed (4x). OysterRock also has an extraordinary advisory board made up of well-known Indian business leaders. The firm’s design, processes and actions are deliberate to align client interest which helps it to focus on making idiosyncratic investments with asymmetric long-term prospects. Previously, Mehul headed equity fund management at HSBC Asset Management in India and worked at Credit Suisse and Raymond James’ India business. Mehul is a mechanical engineer and a management graduate from the Indian School of Business.

The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.

Maithan Alloys: Idle Cash Set To Return As India Rewires Buyback Tax

April 21, 2026 in Asia, Asian Investing Summit 2026, Audio, Equities, Ideas

Amey Kulkarni of Candor Investing presented his investment thesis on Maithan Alloys (India: MAIT) at Asian Investing Summit 2026.

Thesis summary:

Maithan Alloys is a profitable ferro alloys producer that Amey views as a classic Benjamin Graham-style cash bargain with an identifiable near-term catalyst. The shares recently traded at a market cap of roughly $296 million against liquid investments of about $346 million as of 31 December 2025, meaning the market assigned no value to an operating business that has been profitable and cash-generative for the past decade. Amey’s thesis rests on a shift in Indian capital-return taxation that should push promoters toward buybacks and re-rate the equity.

The operating business has produced positive PAT every year for a decade, with TTM revenue of ₹2,049 Cr and TTM PAT of ₹453 Cr. Operating margin spiked to 36% in FY22 on post-COVID supply tightness before normalizing to 10-11%, and the FY21–FY23 windfall seeded the current investment portfolio. The balance sheet carries negligible non-current debt (under $1 million) plus ~$60 million of short-term borrowings tied to working capital and a recent land purchase, not to operating weakness.

The cash bargain exists because three Indian tax changes effectively eliminated tax-efficient capital return: a 2019 buyback distribution tax, a 2020 reclassification of dividends as interest-like income (taxed up to 39%), and a 2024 rule treating buybacks as deemed dividends. Investors stopped underwriting balance-sheet cash. The portfolio itself is notable: ~₹931 Cr in unlisted NSE shares (IPO expected within 6–24 months), ~₹200 Cr across 15-plus PMS vehicles, and 80-plus directly held equities.

The catalyst is the 1 February 2026 Union Budget, which reclassified buyback proceeds as capital gains taxed at 12.5% for long-term holders rather than as deemed dividend. SEBI has separately proposed reviving open-market buybacks. Amey expects buyback announcements to proliferate across cash-rich, low-debt Indian companies over the next several quarters as promoter incentives re-align. Promoter shareholding sits at the 75% regulatory maximum, though certain family members have applied to be declassified as promoters.

On valuation, Amey’s thought experiment of deploying 75% of cash (~₹2,400 Cr) to retire 75% of shares would 4x the share price at constant market cap, or 2x it if market cap halved. Execution is not required for the thesis to pay — an announced $50 million buyback (~15% of cash) could move the stock 50%+. Amey sizes downside against a 50% market drawdown impairing the investment portfolio, and will exit if no substantial buyback is announced by the September 2027 AGM.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Amey Kulkarni operates a boutique investment advisory that partners with select individuals and family offices in their journey of wealth creation through investments in the Indian equity markets. Amey worked in the corporate sector for a decade with experience spanning across India, Europe and African markets. Amey has also worked closely with the top management of L&T (Chairman’s office) and the MD&CEO office at Jindal Steel & Power handling responsibilities of corporate strategy and business planning. Having gained unique insights into the internal workings of large diversified businesses from close quarters, Amey now applies the learnings to run an investment fund at Candor Investing. At Candor Investing, Amey invests in companies that don’t require external capital, have the ability to grow for a long time and are run by honest and hungry management. Being passionate about sharing the learnings and insights gained out of his investment experience, Amey occasionally takes up visiting faculty assignments at various Indian business schools. He is also a contributing author to the Moneylife Magazine which is renowned for pointing out corporate governance issues and championing investor awareness campaigns.

The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.

Gokaldas Exports: CEO-Led Turnaround With Asymmetric Upside

April 21, 2026 in Asia, Asian Investing Summit 2026, Audio, Equities, Ideas

V.P. Rajesh and Saurabh Basrar of Banyan Capital Advisors presented Gokaldas Exports Ltd. (India: GOKEX) at Asian Investing Summit 2026.

Thesis summary (by MOI Global):

Gokaldas Exports is among India’s top three ready-made garment (RMG) exporters, manufacturing and exporting apparel for women (52% of FY25 revenue), men (38%), and children (9%) to global brands including Gap, JC Penney, Columbia, A&F, and Carhartt. Customer relationships are deep — 84% of revenue comes from 10-plus-year customers — with the geographic mix at 73% US, 8% EU and UK, and 19% rest of world. The footprint spans 30+ facilities across India, Kenya, and Ethiopia, with annual capacity of ~87 million garments.

Founded in 1979 and acquired by Blackstone in 2008, the business flatlined for a decade before being sold in 2017. Siva Ganapathy became MD in late 2017 and orchestrated a turnaround, growing revenue at a 19% CAGR over FY17-25 and lifting operating EBITDA margin from -3.3% to 9.5%. Siva owns ~2% via ESOPs. He has since executed three value-accretive deals: Atraco (Jan. 2024, $71 million EV at 7.3x EBITDA) for Kenyan/Ethiopian capacity with duty-free US/UK/EU access; Matrix Clothing (Feb. 2024, Rs. 4.9 bn EV at 6.9x EBITDA) for knitted-garment capability and European reach; and a pending acquisition of BRFL Textiles (Rs. ~10 bn EV at 0.6x revenue at optimal utilization) for backward integration into fabric processing.

Multiple tailwinds support a step-change in profitability through FY28. The China-plus-one supply chain shift, India’s UK FTA (effective Q2 CY26) and EU FTA (effective January 2027), and the US trade deal at a 10% tariff position Gokex to capture share. Backward integration via BRFL is expected to add Rs. 12 bn of external revenue and Rs. 2 bn of EBITDA at a 16.7% margin in FY28. Total revenue is projected to compound at a 27% CAGR to Rs. 64 bn in FY28, with operating EBITDA scaling to Rs. 8 bn at a 12.5% margin, versus a tariff-depressed 8.4% in FY26E.

The shares recently traded at Rs. 660, equating to a market cap of Rs. 48.3 bn (~$517 million) and EV of Rs. 50.8 bn, or 14x TTM EV/Op. EBITDA on a depressed earnings base. Banyan’s base case applies a 25x P/E (versus the 5-year median of 33x) to FY28E EPS of Rs. 38.4 for a target of Rs. 959, implying ~45% upside, or roughly 20% annualized. The bull case at 30x on Rs. 47 EPS yields Rs. 1,411 (114% upside), while the bear case implies a modest -7% return to Rs. 615. The implied EV/Op. EBITDA at the base-case target is ~10x, well within the historical range.

Watch this session:

printable transcript slide presentation audio recording

The following transcript has been edited for space and clarity.

Saurabh Basrar: Standard disclaimer up front: the firm owns the stock we are discussing, so this is not a recommendation to buy or sell.

A quick word on the firm. Banyan Capital is a SEBI-registered PMS firm, 14 years in operation, managing a little over $100 million — $54 million on the PMS side and roughly $50 million in wealth advisory. The portfolio managers have about $5 million of their own capital invested in the same strategies. We run four PMS strategies: Banyan India Portfolio (small-cap), Banyan Edhas Portfolio (absolute-return, market-cap-agnostic), Banyan Leaders Portfolio (large- and mid-cap), and Banyan Yield Plus (special situations). Detailed performance across time periods is on the APMI website. The portfolio managers have a combined six decades of investing experience across multiple cycles, supported by a research team of five analysts.

Before today’s idea, a quick update on the two we presented previously. GHCL Textiles — presented in 2024 at 85 rupees and a market cap of 8 billion — is still around the same price, but the business has improved meaningfully. Sales are up 18%, from 10.5 to 12.4 billion rupees; operating margins have moved from 7.5% to 10%; and profit has more than doubled, from 250 million to 570 million. Our original thesis called for a ramp to roughly 15% long-range EBITDA margins; we are running below that, largely because of US tariffs over the last 12 to 15 months. The thesis has elongated, but we remain bullish — the stock still trades at just over half of book value.

Gujarat Ambuja Exports, presented last year at 110 rupees and a 50 billion market cap, is up 40% as of yesterday. The business is largely maize processing — starch and its derivatives. The maize-processing cycle bottomed out in September, and maize prices are down 15% to 20% over the last four or five months, which should feed meaningfully higher margins and cash flows in the coming year. Two factors drove the price decline: high maize prices over the prior two years pulled in more acreage and production; and the government’s allowance of broken rice for ethanol reduced maize demand from that end-market. The fermentation build-out is on track — the first 30,000-ton plant is commissioned, and the remaining three plants (another 90,000 tons) will be commissioned by December 2026. That is a considerably higher-margin business, so we continue to see meaningful upside from here.

Now to today’s idea — Gokaldas Exports, which we will call Gokex. It is an apparel manufacturer trading at 660 rupees as of April 13, market cap of 48 billion rupees — a little over half a billion US dollars — with promoter shareholding of 9.2%.

The investment rationale. Gokex is among the top three ready-made garment exporters in India with an aspiration to become number one. The industry tailwinds are strong: the US trade deal, FTAs with the UK and EU in progress, and the China-plus-one sourcing shift. Margin expansion will come from backward integration into fabric manufacturing and processing via the recent acquisition of BRFL Textiles. The manufacturing footprint is diversified — over 31 facilities in India plus operations in Kenya and Ethiopia. Growth visibility over the next two to three years is strong, driven by both product mix and backward integration. CEO Siva Ganapathy has an excellent track record — he has led the turnaround over the last seven to eight years and has been a disciplined, value-accretive acquirer. Alignment of interest is solid: he holds about 2% through ESOPs. And the current valuation does not, in our view, capture the upside from the pending BRFL acquisition. On balance, a compelling risk-reward at this stage.

The business. Gokex is a manufacturer and exporter of ready-made garments. Revenue mix: 52% womenswear, 38% menswear, and 9% children’s garments. The customer base is leading international fashion brands and retailers — Gap, JC Penney, Columbia, A&F, and Carhartt among the keys. Over 98% of customers have a five-plus-year relationship with Gokex and 84% have ten-plus years — so the vintage is extremely long. Geographic mix: 73% US, 8% EU and UK, and 19% rest of world including India. Management is actively diversifying toward EU and UK, and the FTAs should accelerate that.

A bit of history. The company was founded by Jhamandas H. Hinduja in 1979 and remained a traditional family-run business through its 2005 IPO, with the Hinduja family retaining majority control. In March 2008, Blackstone acquired a controlling stake, but over the following ten years the business flatlined — EBITDA and PAT losses in most years. Blackstone eventually sold the stake to Clear Wealth Consultancy Services, which was controlled by Mathew Cyriac — a Blackstone partner who had been responsible for the original Gokex investment and left to set up CWCS. Siva was appointed MD in December 2017 and turned the business around over the next several years. Revenue has compounded at 19% over the last eight years, and operating EBITDA margin has moved from losses in FY17 and FY18 to 9.5% today. With that, I’ll hand over to VP to take you through the acquisitions and the forward thesis.

VP Rajesh: Atraco was the first acquisition — announced in August 2023 and consummated in January 2024. The logic: it diversified the manufacturing base outside India, with four facilities in Kenya and one in Ethiopia. The valuation was reasonable at roughly 7.3x EBITDA. On product, Gokex was primarily in fashionwear and outerwear — 80% to 85% of the business — while Atraco brought bottomwear- and topwear-heavy mix, which is why its 9% EBITDA margin was slightly below Gokex’s. But it completed the product portfolio and gave duty-free access to the US, UK, and EU — particularly valuable in EU and UK where Gokex had limited presence. It also added new customers: JC Penney was the only common customer between the two businesses. The acquisition checked the box on product, customer, manufacturing footprint, and duty-free access.

The second acquisition, Matrix Clothing, closed in February 2024. The multiple was again reasonable at 7x EBITDA. Matrix’s EBITDA margin was higher at 12% because it was doing more value-added product not in Gokex’s portfolio. It opened doors further into Europe — 55% of Matrix’s revenue was European, especially UK. And it expanded the product set: Gokex was woven-only, while 85% of Matrix’s revenue came from knitted garments, so the combined business can now go to a customer with a comprehensive woven-plus-knitted offering. Matrix also brought a manufacturing base in the low-cost state of Jharkhand — specifically Ranchi — in addition to its Gurgaon operations.

The third transaction is the most interesting. BRFL was in bankruptcy — in India we call it the NCLT process. Siva first made an investment in the middle of 2024, took management control, and once he saw how important BRFL could be to Gokex’s future, announced a merger last year with an increased investment. It is a complex transaction, and the good news is we expect it to come out of NCLT by September this year. Gokex will pay roughly 600 crores — 6 billion rupees — with enterprise value around 10 billion including some assumed debt. Capacity utilization was very low due to NCLT, but at optimal utilization they are paying only 0.6x revenue. The benefits: certainty of raw-material supply through backward integration into fabric processing; and attractive economics — two-thirds of BRFL’s output will be sold externally, one-third consumed internally. At optimal capacity, BRFL can do roughly 16% EBITDA margin — potentially 18%, but we model 16%. That translates to about 12 billion rupees of additional top line and 2 billion of EBITDA in FY28. If the transaction closes in September 2026, ramp-up takes another six months, so only half of FY27 counts — which is why we focus on FY28 for the full-year benefit.

A word on financing. During the first phase of the turnaround, ROE and ROCE moved up nicely to around 20%. Once the acquisition path began, the pattern has been to fund transactions with debt and then pay down with equity issuance. I should note that in fiscal 2019 and 2022, during the turnaround itself, significant dilution was needed to shore up working capital and pay down earlier debts. But the business today is solid, generating 20%-plus returns. For the pending BRFL transaction, they are issuing roughly 40 lakh shares — a 5% to 6% dilution — with the balance paid in cash supported by debt. One note: in every acquisition except Matrix, Gokex also took on the target’s debt, which is why leverage creeps up before the equity issuance brings it back down.

Before the forward outlook, a bit on end-markets. India exports roughly $37 billion of textiles, of which about $16 billion is apparel — the addressable market for Gokex. EU and US together are about 70% of that $16 billion. Keep those figures in mind. India’s share of US apparel imports has been growing but is still only about 6%, with room to expand as customers pursue supply-chain diversification. On cost, India is competitive versus China and Vietnam. Bangladesh used to be cheaper, but following Bangladesh’s December 2023 wage revision and India’s own wage inflation, the cost stack — primarily wages and electricity — has India cheaper than Vietnam and China and roughly even, or slightly cheaper, than Bangladesh. Before the US tariffs last April, this was clearly the most attractive growth vector. For the EU and UK, Indian exports historically faced 12% duty versus 0% for Bangladesh, Vietnam, and Cambodia — we were structurally disadvantaged. With FTAs now signed with both the UK and EU, the prospects are looking quite bright.

On subsidies: the Indian government has a scheme called RoSCTL, started in 2019. It was set to expire in March but has been extended for six months, and our view is that it continues for the next several years — textiles is a critical employment sector, and the government is unlikely to disturb it given the geopolitical backdrop. Gokex captures roughly 3% to 3.5% of revenue from RoSCTL, but it is an open secret — customers like Gap and A&F have it baked into pricing negotiations, so the real commercial sensitivity is limited. Management estimates that if the scheme were withdrawn, there would be a 200 bps hit to EBITDA margin for two to four quarters before pricing adjusts. There are also smaller incentives — import-duty waivers on machinery, state-level incentives for hiring women, and some power subsidies — but RoSCTL is the material one, and it is already in the customer pricing conversation.

Onto the numbers. In fiscal 2024, Gokex did 24 billion rupees of revenue — Atraco and Matrix were only in Q4, so the first three quarters were standalone. Margin was 10.7% and operating EBITDA 2.5 billion. In fiscal 2025, with Atraco and Matrix contributing for the full year, revenue jumped 62% to 38.6 billion — the majority from the acquisitions, but the base business also grew around 13%. Operating EBITDA margin was down 110 bps, but operating EBITDA rose to 3.7 billion. This year should have been a growth year, but US tariffs changed that — revenue will be roughly 40 billion with margins down to 8.4%. Management’s response was smart. They gave discounts to US customers, structured so that the discounts reverse immediately the day tariffs come off — no delay — which preserved the customer relationships. In parallel, they leaned into EU and UK, since after the customer discount and the 12% duty the net realization was roughly the same as in the US, and they could see the FTAs coming. The second lever was passing some pain to suppliers and driving operational efficiencies. Atraco also helped — its ~800 crore revenue base faced only 10% tariffs across US, UK, and EU. Rupee depreciation contributed as well. We expect full-year operating EBITDA of 3.4 billion.

The reason we are excited is the combination of growth drivers. The US trade deal at 10% tariff is a big positive. The UK FTA should take effect next quarter. The EU FTA is scheduled for January of next year, so effectively fiscal 28 — which is why we anchor the numbers there. BRFL is the fourth driver: by FY28 it is fully integrated and fully ramped, delivering a substantial revenue and EBITDA contribution. They are also adding manufacturing capacity in India and Kenya. Historically, Gokex was primarily Karnataka-based — a high-cost state. They have since expanded into Jharkhand, Haryana, the south, and Madhya Pradesh, capturing state subsidies and diversifying the footprint. Pulling it all together: by FY28, base-business revenue can reach 52 billion rupees — a 14% CAGR. More importantly, base-business operating EBITDA can rise from 3.4 billion this year to 6 billion. Adding BRFL, total revenue can compound at 26% to 27% and operating EBITDA jumps to 8 billion. Margin will have expanded to 12.5%. The 8.4% this year is depressed — it would have been roughly 10.5% without the US tariff drag — so you get that normalization plus another 200 bps of improvement, driven primarily by BRFL and ongoing cost work.

Valuation. As of April 13, market cap is 48 billion rupees with 2.5 billion of debt, so EV is about 51 billion. Earnings and EBITDA are depressed this year, so the optics are elevated — 45x P/E and 14x operating EBITDA on a depressed base. In our base case, 8 billion of operating EBITDA translates to roughly 3 billion of PAT and 38.4 rupees of EPS. The bear case assumes BRFL hiccups or delayed capacity plus a modest margin shortfall, which still delivers 31 rupees of EPS comfortably. The bull case is 65 billion of revenue, 9 billion of operating EBITDA, 3.6 billion of PAT, and 47 rupees of EPS. Frankly, I would be disappointed if they did not clear 40 rupees. On multiples, the five-year median and average are both around 32x, but we think those are too high, so we apply 25x in the base case and 30x in the bull. Run the math and you get an upside of 45% to 115% over two years — roughly 20% to 50%-plus annualized. The stock is at 660; the worst case given everything that has transpired globally is somewhere around 600 to 650, and upside is 960 to 1,400. Implied EV-to-operating-EBITDA at the target is about 10x in the base case and 12.5x in the bull — well within the historical range. A classic situation where downside is contained and the upside is asymmetric.

Risks. The business remains very dependent on the US, so if consumer demand weakens — rates or otherwise — Gokex is exposed. The mitigating factor is that penetration within each customer is low, and the shift toward EU and UK dampens the concentration. The same logic applies to geographic and customer concentration — the largest customer is 25% today and should decline as EU and UK grow. RoSCTL withdrawal is a watch item, as discussed. The one we spend the most time on is key-man risk: Siva is a one-man army building his team, and that work is still in progress. Management and the board have not shied away from equity dilution — we don’t love it, but given the M&A track record we are comfortable. And supply-chain disruption is a global macro risk worth calling out.

Q&A Session:

Q: Could you expand a bit on capital allocation going forward — what you expect the mix to look like over the next couple of years, and whether there is anything you would prioritize differently than management?

A: Management has used equity dilution to fund the strategic objective of becoming India’s number-one exporter. They are still number three — the leader does a little north of a billion dollars of revenue. With the pending acquisitions, Gokex reaches 60 to 70 billion rupees, which is another year or two of growth beyond FY28 before they are at that target. So I would not be surprised to see one or two more acquisitions to add capability or customer penetration, financed with debt and subsequently refinanced through equity. That dilution risk is real. Once they are the largest, I expect a more prudent M&A posture — that’s my expectation, and we interact with management on this question. That said, look at BRFL: they will spend about 10 billion rupees and get at least 2 billion of EBITDA in FY28 — 5x on just the external piece. If they ended up consuming more internally, the implied multiple is even cheaper. As an ex-M&A banker, what I look at is whether the acquisitions are creating value for shareholders. As long as the transactions are synergistic from day one and clearly accretive, I am comfortable.

Q: And in terms of tracking the thesis going forward, what are the key data points to watch?

A: The first milestone is what US customers do with the discount structure — rolling discounts back or settling at 10% in line with the current tariff. We will be watching the Q4 call for that. The second is the EU and UK revenue share — already 14% in Q3, and we expect it to keep climbing, with 20%-plus by FY28 a reasonable target. The third is completion of the BRFL acquisition around September, which reshapes the FY28 growth story. And the fourth is the BRFL ramp — 60% capacity utilization by March, then to 75% by the end of next financial year. Those are the milestones over the next six to nine months.

About the instructors:

V.P. Rajesh started Banyan Capital Advisors in New Delhi, India in November 2011 to manage outside capital using investment principles espoused by likes of Graham, Buffett, Munger, Klarman and Lynch. V.P. relocated to New Delhi from San Francisco in 2007 and started investing full-time in the Indian stock market in his personal portfolio. Prior to that, he was an Investment banker for over 10 years specializing in mergers and acquisitions. During his banking career with J.P. Morgan Chase, Deutsche Bank, Piper Jaffray and Thomas Weisel Partners in New York and San Francisco, he completed transactions worth over $27 billion. V.P. is an MBA from the University of Michigan’s Ross Business School with a distinction and has a B.E. (Hons.) degree from BITS, Pilani, India.

Saurabh Basrar is a Portfolio Manager at Banyan Capital Advisors. He has fifteen years of experience in portfolio management and equity research. His prior experience includes positions at Fidelity, A.T. Kearney, and Citibank. Saurabh is a rank holder chartered accountant, member of the CFA Institute, and a graduate of Sri Ram College of Commerce. He is also the author of the bestselling book, “Masterclass with Super-Investors”.

The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.

Ather: Software-Defined Scooter Maker Riding Electrification Wave

April 21, 2026 in Asia, Asian Investing Summit 2026, Asian Investing Summit 2026 Featured, Audio, Equities, Ideas

Rajeev Mantri of Navam Capital presented his in-depth investment thesis on Ather Energy (India: ATHER) at Asian Investing Summit 2026.

Thesis summary:

Ather Energy is a pure-play electric two-wheeler (E2W) company founded in 2013 by IIT Madras engineers Tarun Mehta and Swapnil Jain. The company designs premium, software-defined scooters for India’s 21.7 million-unit two-wheeler market, the world’s largest. Its portfolio spans the flagship 450 series (450X, 450S, 450 Apex) and the Rizta family scooter. In Q3 FY26, Ather sold a record 67,000+ scooters, taking its E2W market share to 18.8%. Rajeev argues that Ather is India’s most capable pure-play electric transportation business, with an integrated product, software, and charging-network stack that both startups and legacy OEMs will struggle to replicate.

The Indian E2W market has compressed a decade of evolution into three phases: inception (2013–2019), inflection (2020–2023), and reset (2023–2025). Subsidy cuts, FAME-II’s wind-down, and compliance crackdowns culled the sector from 50+ players to three or four major OEMs. Ather scaled through the churn by investing upfront in R&D and IP while rivals like Ola Electric chased revenue through aggressive pricing. With E2W penetration at 6.8% of India’s two-wheeler market versus China’s 50%+, and category volumes compounding at 20%+ annually, the runway is long.

Ather’s differentiation rests on four pillars: vertical integration, premium brand positioning (priced 30–40% above peers), a software-defined ecosystem, and capital-efficient operations. Patents span software (27%), electronics (20%), chassis (18%), battery (17%), and powertrain (8%). Engineering iteration has delivered a 47% range improvement, 30% gain in peak power, 25% top-speed increase, and 30% BOM cost reduction across product generations. Distribution doubled from 351 experience centers in FY25 to nearly 700 by April 2026, catapulting share from sub-5% to 18.8%.

Promoter ownership is stable, with founders Mehta and Jain holding 10.7% and Hero MotoCorp 30.1%. Rajeev flags risks including an unproven path to profitability, competitive intensity from TVS (iQube) and Bajaj (Chetak), China-dependent battery cell supply, and orthogonal technology shifts.

Ather recently traded at around ₹871 per share, implying a market cap just below $4 billion and EV/EBITDA of 12.8x. TTM revenue was ₹31.7B with a net loss of ₹6.5B; adjusted gross margin was 24%. The shares have roughly tripled since the May 2025 IPO and sit near all-time highs. Rajeev views the IPO proceeds of ~$350–400M as sufficient, with remaining losses reflecting distribution investments that should pay off quickly as operating leverage drives the business toward positive unit economics.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Rajeev Mantri is managing director of Navam Capital, an India-focused investment firm. Prior to founding Navam Capital, Rajeev worked as a venture capitalist at New York-based Lux Capital, focusing on investments in energy, water and nanomaterials. Rajeev has contributed columns and articles on technology, investing, venture capital and political economy to The Wall Street Journal, Mint, Swarajya, Financial Times, The Indian Express, The New York Times International Weekly, Roubini Global Economics and other publications. In August 2010, Rajeev co-founded Vyome Therapeutics, a biopharmaceuticals company, and served as Vyome’s president through the company’s formative years. Rajeev graduated with a BS in materials science and engineering from Northwestern University, and an MBA from Columbia Business School, specializing in private equity and value investing. Rajeev is the author (with Harsh Madhusudan) of the book, A New Idea Of India — Individual Rights In A Civilisational State, an international best-seller on the history and future of modern India covering a diverse range of topics in economics, foreign policy and politics.

The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.

Kazakhstan: Resource-Rich, Growing Economy at Mid-Single-Digit P/Es

April 20, 2026 in Asia, Asian Investing Summit 2026, Asian Investing Summit 2026 Featured, Audio, Equities, Ideas, Transcripts

Isaac Schwartz of Robotti & Company discussed his investment thesis on Kazakhstan and three avenues for participation: Kazatomprom, Air Astana, and the Kazakh banking sector at Asian Investing Summit 2026.

Session summary:

Isaac presented an investment case for Kazakhstan and three avenues for participation: Kazatomprom, Air Astana, and the Kazakh banking sector. The country suffers from an “invisibility tax” that depresses valuations and rewards long-term fundamental investors. Sharing a 2,000-mile border with China and a GDP per capita on par with Turkey and Mexico, the economy approaches $500 billion. Kazakhstan is the world’s largest uranium producer (40% of global output) and produces ~2 million bbl/day of oil.

Kazatomprom, the National Atomic Energy Company, is dual listed in London and in-country, 63% owned by the Sovereign Wealth Fund, with a ~$20 billion market cap. It produces half of Kazakhstan’s uranium output. Recent revisions to subsoil rights laws raised its mandated stake in new uranium developments from 50% to 75%, ensuring it captures a growing share of the country’s industry. For investors constructive on nuclear, it offers direct exposure to the leading global producer.

Air Astana, the national airline, has ~$1.5 billion in revenues and a ~$500 million market cap, dual listed in London and in-country, ~42% owned by the Sovereign Wealth Fund. Built from a $17 million investment 25 years ago, it operates ~80 Airbus A320s with twin hubs in Almaty and Astana and a 100%-owned LCC, FlyArystan. Transit business contributes more than half of revenues. The balance sheet has no direct debt outside aircraft leases, a large cash position, and management has been repurchasing shares.

Four banks dominate Kazakhstan — Halyk, Kaspi, Bank CenterCredit, and ForteBank. Halyk’s loans have grown from ~$6 billion to ~$30 billion over a decade, with income rising from $350 million to >$2 billion and a two-decade EPS CAGR of 14%. Banking assets sit at ~$150 billion vs. >$400 billion of GDP — loans/GDP below one-third, well below economies at comparable income levels. Isaac sees a dual tailwind: mid-single-digit GDP growth and credit penetration convergence.

Air Astana’s normalized earnings imply a mid-single-digit P/E, a steep discount to global peers. Bank CenterCredit recently traded at a low single-digit P/E, with post-trough appreciation driven by fundamentals rather than multiple expansion. Halyk’s $4 stock-price trough a decade ago now corresponds to its $4 annual dividend, an effective 100% yield on original cost. Isaac frames Kazakhstan’s “invisibility tax” as the source of attractively priced entry into a regional hegemon.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Isaac Schwartz is a portfolio manager and seeks to achieve long-term gains by investing in undervalued securities (primarily stocks) of companies throughout the world. Isaac serves as a director of Menu Group (U.K.) Ltd., the leading online food delivery platform in several former Soviet Republics, and of Complete Start Inc., a plant-based health food company in the U.S. Prior to joining Robotti & Company in 2002, Isaac worked for Schiff’s Insurance Observer, an investigative journal, where he did research on the property-casualty and annuity insurance industries. Isaac graduated from Wharton with a BS in Economics.

The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.

Natco Pharma: Complex Molecules, Owner-Operator, Capital Discipline

April 20, 2026 in Asia, Asian Investing Summit 2026, Audio, Equities, Ideas, Transcripts

Nandan Madhiwalla of East72 Capital Management presented his thesis on Natco Pharma (India: NATCOPHARM) at Asian Investing Summit 2026.

This session was hosted by Alex Gilchrist.

Thesis summary:

Natco Pharma, a ~$1.9 billion market cap Indian pharmaceutical company, pursues a differentiated first-to-file (FTF) strategy in US generics paired with compulsory licensing and patent litigation in India. Founded in 1981 by V.C. Nannapaneni and now run by his son Rajeev, Natco has compounded revenue from 176 crore to 4,764 crore and PAT from 24 crore to 1,883 crore. Promoters hold ~49.5%, with a track record of conservatism, candor, and minimal debt. Nandan views the founder-led management team as trustworthy and prudent capital allocators who have not cheated minority shareholders across a multi-decade listed history.

The business has two engines. In India, Natco litigates to launch complex drugs 80–95% below innovator pricing in hospital-driven niches where a large field force is not required—cases include Nexavar (compulsory license), Sovaldi (in-licensed from Gilead), and Everysdi (risdiplam). In the US, Natco files Paragraph IV ANDAs on the NCE-minus-1 date with front-end partners (Mylan, Teva, Viatris, Breckenridge) sharing economics roughly 50/50 to derisk litigation. Lenalidomide (Revlimid), under a volume-linked settlement with Celgene/BMS, generated ~3,500 crore of cash flow between FY23 and FY26.

Natco holds sole FTF status on drugs representing ~$20 billion of global innovator revenue and shared FTF on ~$30 billion, with key assets in carfilzomib, olaparib, apixaban, pomalidomide, and semaglutide. Nandan conservatively models ~$4 billion of cumulative Natco revenue at ~50% EBITDA margins over seven to eight years—roughly $2 billion of cash flow, approximating the current market cap. Near-term catalysts include pomalidomide in the US (launched March 2026) and generic semaglutide in India priced 80–90% below the innovator.

Management deployed Revlimid proceeds into a 37.5% stake in Adcock Ingram at ~8x EV/EBITDA, retaining ~2,500 crore for another global branded acquisition. R&D runs at ~8% of sales. Management has refused inflated Indian M&A multiples, raised equity only when valuations were high, and repurchased stock when cheap.

The shares recently traded at Rs 1,080, equating to ~19,000 crore market cap and ~12x TTM PAT of Rs 1,550 crore. The stock has already derated from ~Rs 1,500 ahead of the Revlimid cliff, and Natco has historically capped out at 10–12x P/E given the non-linear nature of US profits. Nandan’s case is that a growing recurring base (semaglutide India, Adcock Ingram consolidation, oncology abroad) combined with ~$2 billion of prospective FTF cash flow—roughly equal to today’s market cap—offers favorable risk/reward if management executes on both fronts.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Nandan Madhiwalla is a co-founder and managing partner of East72 Capital Management and Advisors. East72 Capital is a long only India focused fund. Previously, Nandan founded and served as the Principal Officer of a SEBI RIA firm from 2018 to 2024, providing equity research-based investment advisory services. Nandan has also held the position of Research Analyst at PPFAS Mutual Fund from 2015 to 2018, where he focused on Indian and US stocks in the financial and media sectors. Additionally, he contributed to investment models and reports at Lebenthal Asset Management and conducted buyside equity research at The Roosevelt Investment Group. Nandan holds a CFA Charter and a Master of Science in Financial & Risk Engineering from New York University. He also earned a bachelor’s in computer science engineering from D J Sanghvi College of Engineering in Mumbai.

The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.

Hindustan Foods: Leading FMCG Contract Manufacturer at Discount

April 20, 2026 in Asia, Asian Investing Summit 2026, Audio, Equities, Ideas, Transcripts

Vinod Moras of Highwest Global Management presented his investment thesis on Hindustan Foods Limited (India: HNDFDS) at Asian Investing Summit 2026.

Thesis summary:

Hindustan Foods is India’s largest and most diversified FMCG contract manufacturer, operating over 40 plants across more than 10 states and serving 50+ clients including Hindustan Unilever, Reckitt, Danone, PepsiCo, Emami, Dabur, Bata, and Skechers. The business produces soaps, shampoos, detergents, ice cream, food and beverages, OTC healthcare, shoes, and household insecticides. HFL was a struggling single-plant Goa operation for nearly three decades until the Vanity Case Group, led by managing director Sameer Kothari, acquired the controlling stake from the Dempo Group in 2013 through a reverse merger. Under the new team, HFL has grown revenue and earnings at a ~36% CAGR over the last five years, yet the stock has advanced just 4% annualized, creating an attractive gap.

HFL is a proxy for India’s consumer story without having to pick a winning brand. The Indian FMCG market is ~$150 billion growing 10-12%, with per capita consumption still a fraction of regional peers. The $25 billion Indian FMCG contract manufacturing market remains ~80% unorganized, and asset-light strategies among brand owners, D2C and quick-commerce proliferation, private-label expansion by retailers, and GST-driven formalization are all pushing outsourcing volumes toward organized players of scale. HFL is the one-stop beneficiary.

The business rests on three models. Dedicated manufacturing — 73%+ of revenue on 7-10 year take-or-pay contracts earning a fixed 15-17% ROE — provides full earnings visibility with no demand or inventory risk. Anchor-tenant (~17%) and private label (<10%) deliver 18-20%+ ROE with incrementally higher risk. Switching costs are high, client churn minimal, and management has a track record of turning around acquired distressed assets.

Gross block has grown ~5x in five years, with more than half deployed into ice cream (already the largest contract manufacturer in India within five years) and footwear, two underpenetrated categories growing well above FMCG. Vinod expects PAT to compound at a 36% CAGR through FY28 as capacity ramps, with ROE moving from ~15% to above 20%. Key risks are HUL client concentration (~25% of revenue), mix shift toward higher-risk models, capex execution, leverage (managed below 1x debt-to-equity), and the inherently volatile shoe business.

The shares recently traded at INR 502, or ~21x FY28 earnings, against FMCG contract manufacturing peers at ~29x and branded FMCG peers at ~42x. Given a 36% FY26-FY28 PAT CAGR that exceeds both peer groups, Vinod views HFL as offering an attractive risk-reward on an earnings compounder with genuine moats.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Vinod Moras is a seasoned value investor with over a decade of experience in Asian equities. He is currently an Investment Manager at Highwest Global Management, overseeing the firm’s India portfolio within its Asia-focused, long-only strategy. Previously, he was Head of Investments at Sixteenth Street Capital, leading research and portfolio strategy for South and Southeast Asia. Vinod also held investment roles at KIARA Advisors and APS Asset Management. Vinod brings operational experience to investing, having worked in the automotive and oil & gas industries before transitioning to finance. He has been a member of the Value Investors Club (VIC) and holds an undergraduate degree in engineering and master’s degree in finance from NYU Polytechnic Institute.

The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.

Kitazato Corporation: Structural IVF Growth at Discount To Global Peers

April 17, 2026 in Asia, Asian Investing Summit 2026, Asian Investing Summit 2026 Featured, Audio, Equities, Ideas, Transcripts

Patrick Rial of TriVista Capital presented his in-depth investment thesis on Kitazato Corporation (Japan: 368A) at Asian Investing Summit 2026.

Thesis summary:

Kitazato is Japan’s leading provider of consumables for in vitro fertilization (IVF), generating over 60% of sales internationally and posting a 56% operating margin — the sixth-highest among non-financial Japanese listings. Patrick estimates the global fertility treatment market at roughly $49 billion, with 5-8% expected growth driven by later marriage, declining male sperm counts, rising egg-freezing adoption, expanding insurance coverage, and ongoing technological improvement. Kitazato’s sales have compounded at an 8.9% CAGR over the last decade.

The company’s moat stems from the vitrification revolution it pioneered with Japan’s Kato Ladies Clinic around 2000. Vitrification flash-freezes eggs in a glass-like state using liquid nitrogen, eliminating the ice-crystal damage of slow freezing and enabling near-100% thaw survival. Industry adoption from 2005 made it the global standard of care. Roughly 65% of Kitazato’s sales tie to vitrification, where it holds 60% share in Japan, 70% in Europe, 80% in China, and 85% in India. Across Japanese product categories, share ranges from 50% to 96%, including a near-monopoly in Cryotop storage devices.

Patrick views founder Futoshi Inoue, 55, as an exceptional operator aligned with shareholders. Inoue owns 58.9% of the company, describes shareholders as co-managers, and is unhappy with post-IPO share performance. FY results due in May should beat a -7.1% operating profit guide (Patrick models +4.5%); a dividend payout lift from the current 40% toward 50-70% is plausible given ¥12 billion of net cash and minimal capex; a potential cryobank business could open a new profit pool; and US growth should accelerate under new distribution partner DeviMed. Principal risks include competition, technological disruption, margin compression, and a possible further stake sale by Inoue.

The shares recently traded at 6.9x EV/EBIT, 13.3x P/E, 2.77x P/B, and a 3.0% dividend yield, with a ¥53 billion market cap. Public peers Cooper Companies and Vitrolife trade at 17.7-23.5x EV/EBIT and 24-38x P/E despite lower margins, while recent industry M&A has taken place at 5x+ sales, implying 18x+ EBITDA. Patrick’s DCF, assuming 4-8% sales growth and 57-59% operating margins, yields a ¥1,387-¥2,238 fair value range, or 3-66% upside.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Patrick Rial is the portfolio manager of the Hosomichi strategy at TriVista Capital, a boutique asset manager founded in 2019 by Masaki Gotoh. Patrick is joining this month to launch the firm’s second strategy. Patrick previously spent 10 years at Varecs Partners as an analyst. He has presented at this conference numerous times. Patrick began his career as a journalist and subsequently worked at Morgan Stanley and J.P. Morgan before becoming an investor. He graduated from Georgetown University and is a CFA charterholder.

The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.

Chagee: Premium Global Tea Platform at Single-Digit P/E Ex-Cash

April 17, 2026 in Asia, Asian Investing Summit 2026, Asian Investing Summit 2026 Featured, Audio, Diary, Equities, Ideas, Transcripts

Roshan Padamadan of Luminance Capital presented his investment thesis on Chagee (US: CHA) at Asian Investing Summit 2026.

Thesis summary:

Chagee is a premium fresh-leaf tea platform based in China aiming to become the “Starbucks of tea” through global expansion. Founded in 2017 in Yunnan by Zhang Junjie — now China’s youngest billionaire, retaining ~35% ownership — Chagee operates 7,453 stores globally, with ~6,700 in Greater China, and brews via a proprietary “tea espresso” machine delivering ±2% consistency across geographies versus an estimated ±10% for barista-made products. Priced around 20 yuan (~$4-5) per drink, it targets the upwardly-mobile Chinese consumer and an under-branded global tea category with no dominant premium player.

The model is 82% franchised, with Chagee collecting royalties and supplying tea and ingredients at high margins, while its app (~177M registered users, ~45M active) drives ~90% of footfall. Store closure rates run at ~2%, well below the industry median, and franchise unit economics hold up even after monthly per-store revenues normalized from over RMB 500K to the RMB 350-400K range. Company-owned stores — 18% of revenue but +126% YoY in Q4 2025 — handle brand control in Singapore (~20 stores), the US (seven in LA), and Korea (new launch).

China is shifting from growth to cash generation, while international rollout — Korea, Malaysia (300-store franchise plan), Thailand JV, US, Middle East, and Europe — carries the valuation narrative. Same-store sales in China fell 20-24% in 2025 as Alibaba- and Meituan-led discount wars pulled coupon-seeking consumers toward mass-market peers HEYTEA and Mixue, but Chagee declined to participate, protecting brand equity. Chinese regulators have since pressured such discounting, which Roshan expects to improve sentiment during 2026.

FY2025 revenue was RMB 12.91B (~$1.85B), net income RMB 1.19B (~$170M), and non-GAAP net income RMB 1.91B (~$273M). The shares recently traded at ~$10 versus the April 2025 IPO at $28, implying a market cap of ~$1.7B, offset by a cash balance comprising a large share of that market cap, no debt, and ~$400M of annual FCF distributed as a dividend last December (~8-9% yield). Multiples are ~0.92x EV/Revenue, ~5.5x EV/EBITDA, and a single-digit P/E ex-cash. JPMorgan recently set a $16 target on stabilizing same-store sales in 2026, implying ~60% upside. Roshan views Chagee as a combination of value and growth with multi-bagger potential over 5-10 years, cushioned by cash and dividend yield.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

About the instructor:

Roshan Padamadan is Chairman at Luminance Capital. He is a global investor and splits his time between New York, Singapore and India. Previously, he served as COO, Risk and Compliance officer at Sixteenth Street Capital, based in Singapore. His erstwhile Luminance Global Fund had a global unconstrained investment strategy, looking at special situations and deep value. Prior to launching Luminance in 2013, Roshan also spent more than seven years with the HSBC Group, including more than three years with HSBC Asset Management, as a Product Specialist. He worked for the highly commended Offshore Indian Equity team which ran US$5+ billion from Singapore, including a US$100+ million award-winning India hedge fund. Roshan has earned an MBA in Management from Indian Institute of Management, Ahmedabad. He holds the CFA and CAIA charters and speaks over five languages.

MOI Global